FDA Accepts BLA for Datopotamab Deruxtecan in Pretreated Advanced Nonsquamous NSCLC

A BLA seeking the approval of datopotamab deruxtecan in pretreated nonsquamous non–small cell lung cancer is under review by the FDA.

Related Keywords

Ken Takeshita ,Daiichi Sankyo ,Susan Galbraith ,Astrazeneca ,Prescription Drug User Fee Act ,Datopotamab Deruxtecan ,Dato Dxd ,Non Small Cell Lung Cancer ,Nsclc ,Lung Cancer ,Biologics License Application ,Tropion Lung01 Trial ,